287918-21-2

Basic information

• Product Name: 3-(4-methoxybenzyl)-2-thioxoimidazolidin-4-one
• Synonyms: 3-(4-methoxybenzyl)-2-thioxoimidazolidin-4-one
• CAS NO: 287918-21-2
• Molecular Weight: 236.294
• Mol File: 287918-21-2.mol

Chemical Properties

• CAS DataBase Reference: 3-(4-methoxybenzyl)-2-thioxoimidazolidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-methoxybenzyl)-2-thioxoimidazolidin-4-one(287918-21-2)
• EPA Substance Registry System: 3-(4-methoxybenzyl)-2-thioxoimidazolidin-4-one(287918-21-2)

Safety Data

• Hazardous Substances Data: 287918-21-2(Hazardous Substances Data)

Upstream product

• 3694-57-3 1-(isothiocyanatomethyl)-4-methoxybenzene 
• 5680-79-5 glycine ethyl ester hydrochloride 

Downstream Products

• 1356003-69-4 (4Z)-1-(4-methoxybenzyl)-4-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazol-5-one 
• 1356003-71-8 (5Z)-3-(4-methoxybenzyl)-5-(4-methoxybenzylidene)-2-thiohydantoin 

Relevant articles and documents

Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds

Somatic mutations of isocitrate dehydrogenase 1 (IDH1) at R132 are frequently found in certain cancers such as glioma. With losing the activity of wild-type IDH1, the R132H and R132C mutant proteins can reduce α-ketoglutaric acid (α-KG) to d-2-hydroxyglutaric acid (D2HG). The resulting high concentration of D2HG inhibits many α-KG-dependent dioxygenases, including histone demethylases, to cause broad histone hypermethylation. These aberrant epigenetic changes are responsible for the initiation of these cancers. We report the synthesis, structure-activity relationships, enzyme kinetics, and binding thermodynamics of a novel series of 2-thiohydantoin and related compounds, among which several compounds are potent inhibitors of mutant IDH1 with Ki as low as 420 nM. X-ray crystal structures of IDH1(R132H) in complex with two inhibitors are reported, showing their inhibitor-protein interactions. These compounds can decrease the cellular concentration of D2HG, reduce the levels of histone methylation, and suppress the proliferation of stem-like cancer cells in BT142 glioma with IDH1 R132H mutation.

Quinolinone compound and application thereof

The invention discloses a quinolinone compound containing rhodanine and similar fragments thereof and pharmaceutically acceptable salts thereof, and relates to the technical field of organic chemistry. The quinolinone compound is shown as general formula I in the specification, wherein substituent groups R1, X and R2 have meanings given in the specification. The invention also relates to application of the compound shown as the general formula I and the pharmaceutically acceptable salts thereof in preparing medicines for treating diseases caused by abnormal expression of IDO, in particular toapplication in preparing medicines for treating and/or preventing cancers.

Thiohydantoins: Selective N- and S-functionalization for Liebeskind-Srogl reaction study

Thiohydantoins formed by the Schlack-Kumpf protocol were selectively functionalized at the nitrogen, sulfur, or carbon atom to test the Liebeskind-Srogl reaction possibilities. Georg Thieme Verlag Stuttgart. New York.